Tempus AI rises after deal with Predicta to expand access of genome test

Tempus AI

15/04/2026 15:03

** Shares of AI-focused biotech firm Tempus AI TEM.O rise 6.56% to $52.78

** TEM and privately-held diagnostics firm Predicta Biosciences collaborate to commercially expand their co-branded genome sequencing test, GenoPredicta

** Companies say the test is used to study and track residual cancer after treatment using blood or bone marrow samples

** Adds that the test can detect genetic changes from very small amounts of tumor material, which could widen use in patients with low disease burden

** The test has been clinically validated in multiple myeloma and related disorders - TEM

** Including session's move, TEM shares down 10.5% YTD

(Reporting by Kunal Das in Bengaluru)

((Kunal.Das2@thomsonreuters.com;))